Acceptability of Atropine Eyedrops Administered Sublingually for Sialorrhea Treatment Related to Neurological Conditions
Pharmacology Research & Perspectives · 2026-06 · 14 (3)
DOI: 10.1002/prp2.70250 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 22.05.2026. Verfasst von Hugues Michelon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacie, Hôpital Sainte-Périne, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Paris, France. Hauptthemen laut MEDLINE: Atropine, Nervous System Diseases, Patient Acceptance of Health Care, Sialorrhea. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Off‐label use of anticholinergic agents (atropine eye drops) administered sublingually are a first‐line treatment in standard clinical practice in France to treat sialorrhea in patients with neurological conditions. The ability and willingness to using and administering such medication have become key factors to ensure safe and effective therapy. Given that the critical aspects for ophthalmic product development differ from those for oral medicine, the objectives of this study were to investigate patient acceptability of atropine eye drops for treating sialorrhea. A multi‐centric, cross‐sectional study using the CAST—ClinSearch Acceptability Score Test methodology was conducted in France between February 2021 and April 2023. In total, 31 evaluations were collected. Most patients were males (74.2%) and the mean age was 51.6 ± 20 years. Poor acceptability was reported in real‐life settings. A lack of a suitable administration device combined with excessive saliva flow and patient disabilities made it difficult to ensure the required dose intake. Due to the bitter taste of the drug, poor palatability of the product appeared to be a key concern for oral administration. Designing a suitable form of atropine in accordance with the specificities of patients with neurological disabilities is needed to ensure the effective treatment of sialorrhea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Pharmacie, Hôpital Sainte-Périne, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Paris, France.
- Service de Pharmacie, Hôpital Raymond Poincaré, AP-HP, Université Paris-Saclay, Paris, France.
- Unité de Soins Prolongés Complexes, Hôpital Sainte-Périne, AP-HP, Université Paris-Saclay, Paris, France.
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, AP-HP, Université Paris-Saclay, Garches, France.
- Unité de R&D Galénique, Agence Générale Des Equipements et Produits de Santé (AGEPS), AP-HP, Paris, France.
- ClinSearch, 110 Avenue Pierre Brossolette, Malakoff, France.
ORCID-Profile: Hugues Michelon
Zitieren
APA
Michelon, H., Lefèvre-Dognin, C., Paquereau, J., Guidoni, R., Boudy, V., Ruiz, F., & Vallet, T. (2026). Acceptability of Atropine Eyedrops Administered Sublingually for Sialorrhea Treatment Related to Neurological Conditions. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70250
Vancouver
Michelon H, Lefèvre-Dognin C, Paquereau J, Guidoni R, Boudy V, Ruiz F, et al. Acceptability of Atropine Eyedrops Administered Sublingually for Sialorrhea Treatment Related to Neurological Conditions. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70250
BibTeX
@article{Michelon2026,
author = {Michelon, Hugues and Lefèvre-Dognin, Clémence and Paquereau, Julie and Guidoni, Raphaëlle and Boudy, Vincent and Ruiz, Fabrice and Vallet, Thibault},
title = {Acceptability of Atropine Eyedrops Administered Sublingually for Sialorrhea Treatment Related to Neurological Conditions},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {3},
doi = {10.1002/prp2.70250}
}
EUVIMED